It has demonstrated antitumor activity in RAS/MAPK-driven tumor models and is selective for SHP2 with no significant inhibition against any off-target kinase or phosphatase among the 300 kinases and 12 phosphatases tested. This evidence concerns the gene PTPN11 and neoplasm.